CybernaX and CanSino (Shanghai) partner on nucleic acid medicines for the global animal health market
9 July 2024 — CybernaX Biotechnologies announced that it has entered into a licensing and collaboration agreement with CanSino (Shanghai) Biological Technology Co., Ltd. covering lipid development for veterinary infectious disease vaccines. Under the agreement, CybernaX will supply its leading veterinary vaccine lipids to support and advance animal health worldwide.
CybernaX has completed global freedom-to-operate assessment and wet-lab validation for several of these veterinary vaccine lipids. The validation results show high delivery efficiency and a good safety profile, while remaining cost-effective.
We look forward to working with CanSino (Shanghai) to advance nucleic acid vaccines for animal health globally. By combining the innovative technologies each of us has developed independently, we believe we can move faster and further, and contribute to animal health worldwide.
— CybernaX founding team
About CybernaX
CybernaX Biotechnologies develops non-viral nucleic acid delivery technology, built on two lipid platforms: ELITE (CX Ionizable Lipid), an embodied-AI screened ionizable lipid library, and ENDURE (CX Stabilizing Lipid), a PEG-free monodisperse lipid built for long-term repeat dosing. The company licenses and co-develops its lipid platforms with biopharmaceutical and biotechnology partners worldwide.